Stockreport

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

uniQure N.V. - Ordinary Shares  (QURE) 
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: uniqure.com/investors-newsroom/overview.php
PDF Who is Involved: uniQure N.V. (NasdaqGS: QURE) investors that purchased between September 24, 2025 and October 31, 2025When to Act: Deadline to file Lead Plaintiff appli [Read more]